Stryker Corporation

NYSE:SYK Stock Report

Market Cap: US$112.9b

Stryker Future Growth

Future criteria checks 2/6

Stryker is forecast to grow earnings and revenue by 16.3% and 7.9% per annum respectively. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be 21.5% in 3 years.

Key information

16.3%

Earnings growth rate

16.13%

EPS growth rate

Medical Equipment earnings growth16.0%
Revenue growth rate7.9%
Future return on equity21.48%
Analyst coverage

Good

Last updated13 May 2026

Recent future growth updates

Analysis Article • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...

Recent updates

Analysis Article • May 04

Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models

As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...
Narrative Update • Apr 21

SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside

Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.
Narrative Update • Apr 06

SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside

The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.
Narrative Update • Mar 22

SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside

Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.
Narrative Update • Mar 07

SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside

The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.
Narrative Update • Feb 20

SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside

Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.
Analysis Article • Feb 09

Stryker's (NYSE:SYK) Earnings Seem To Be Promising

Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...
Analysis Article • Feb 07

Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88

Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...
Narrative Update • Feb 06

SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment

Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.
Narrative Update • Jan 22

SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential

Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.
Narrative Update • Jan 08

SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside

Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.
Seeking Alpha • Jan 07

Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker

Summary Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako’s continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside. With expected 9%+ revenue growth for FY’26 and EBITDA margins nearing 30%, SYK’s diversified base and disciplined strategy support an attractive risk/reward profile. Read the full article on Seeking Alpha
Narrative Update • Dec 19

SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential

Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.
Analysis Article • Dec 14

Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88

Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...
Analysis Article • Sep 08

Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 08

Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality

NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...
Analysis Article • Jul 09

Estimating The Intrinsic Value Of Stryker Corporation (NYSE:SYK)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Stryker fair value estimate is US$371 With US$390 share price...
Analysis Article • Jun 16

With Stryker Corporation (NYSE:SYK) It Looks Like You'll Get What You Pay For

Stryker Corporation's ( NYSE:SYK ) price-to-earnings (or "P/E") ratio of 50.4x might make it look like a strong sell...
Seeking Alpha • Jan 27

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Summary Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future. Despite current high valuations, long-term growth prospects remain solid, making it a hold for now, but a buy under $350. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Stryker: Starting 2025 With A Bolt-On Deal For Inari Medical

Summary Stryker's $4.9 billion acquisition of Inari Medical aims to enhance its Neurovascular business and solidify its impressive organic growth profile. Despite a strong track record, Stryker's current valuation at 30 times earnings is rather full, prompting a wait for a more favorable earnings multiple. Stryker's diversified portfolio and consistent organic growth, even during the pandemic, underscore its robust business model and strategic M&A execution. With manageable debt and strong financial performance, Stryker's recent acquisitions are considered strategic, though current stock prices may be fully valued. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:SYK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202831,9376,5355,7147,83719
12/31/202729,5645,5274,9116,75326
12/31/202627,2674,8713,6685,76225
3/31/202625,2703,3374,5715,375N/A
12/31/202525,1163,2464,2835,044N/A
9/30/202524,3812,9434,0734,832N/A
6/30/202523,8182,9184,0244,766N/A
3/31/202523,2182,8593,5774,288N/A
12/31/202422,5952,9933,4874,242N/A
9/30/202421,9743,5903,2053,839N/A
6/30/202421,3893,4482,8033,415N/A
3/31/202420,9633,3612,8583,470N/A
12/31/202320,4983,1653,1363,711N/A
9/30/202319,8852,5852,5683,186N/A
6/30/202319,4552,7092,4173,025N/A
3/31/202318,9522,6272,2672,866N/A
12/31/202218,4492,3582,0362,624N/A
9/30/202217,9482,4572,0152,621N/A
6/30/202217,6292,0792,0672,665N/A
3/31/202217,4302,0152,4533,014N/A
12/31/202117,1081,9942,7383,263N/A
9/30/202116,6691,9003,0163,500N/A
6/30/202116,2462,0832,9733,396N/A
3/31/202114,7161,4082,7123,138N/A
12/31/202014,3511,5992,7903,277N/A
9/30/202014,2201,7562,2542,775N/A
6/30/202014,0701,6011,9602,575N/A
3/31/202014,9562,1641,7982,469N/A
12/31/201914,8842,083N/A2,191N/A
9/30/201914,5493,426N/A2,502N/A
6/30/201914,2043,550N/A2,491N/A
3/31/201913,8763,522N/A2,626N/A
12/31/201813,6013,553N/A2,610N/A
9/30/201813,2761,236N/A2,243N/A
6/30/201813,0401,080N/A1,704N/A
3/31/201812,7301,019N/A1,705N/A
12/31/201712,4441,020N/A1,559N/A
9/30/201712,1301,779N/A1,538N/A
6/30/201711,9571,700N/A1,961N/A
3/31/201711,7851,689N/A1,804N/A
12/31/201611,3251,647N/A1,915N/A
9/30/201610,8831,659N/A1,928N/A
6/30/201610,4701,605N/A917N/A
3/31/201610,0621,617N/A781N/A
12/31/20159,9461,439N/A981N/A
9/30/20159,8491,177N/A907N/A
6/30/20159,818933N/A1,940N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYK's forecast earnings growth (16.3% per year) is above the savings rate (3.5%).

Earnings vs Market: SYK's earnings (16.3% per year) are forecast to grow slower than the US market (16.7% per year).

High Growth Earnings: SYK's earnings are forecast to grow, but not significantly.

Revenue vs Market: SYK's revenue (7.9% per year) is forecast to grow slower than the US market (11.6% per year).

High Growth Revenue: SYK's revenue (7.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYK's Return on Equity is forecast to be high in 3 years time (21.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 03:38
End of Day Share Price 2026/05/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stryker Corporation is covered by 58 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Jeffrey JohnsonBaird
Matthew MiksicBarclays